Archer Aviation is executing Phase 4 FAA certification, with commercialization likely by 2028 and strong upside potential. Read more on ACHR stock here.
Opportunities in the Medullary Thyroid Cancer market arise from diverse pipeline developments by 8+ companies. Focus areas include novel therapies like Regorafenib and next-gen RET inhibitors ...
Meshy, an AI-powered 3D content platform, today announced continued expansion of its AI-assisted 3D creation workflow to help ...
Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that ...
Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda 1 (pembrolizumab), have met their primary endpoints.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results